BC
HAE icon

Bridgefront Capital’s Haemonetics HAE Stock Holding History

Bridgefront Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,363
Closed -$809K – 623
2026
Q1 		$809K Buy
14,363
+4,133
+40% +$269K 0.2% 161
2025
Q4 		$820K Buy
10,230
+5,492
+116% +$369K 0.21% 164
2025
Q3 		$231K Buy
+4,738
New +$293K 0.07% 480
2025
Q2 		– Sell
-8,178
Closed -$520K – 706
2025
Q1 		$520K Buy
8,178
+3,113
+61% +$212K 0.15% 240
2024
Q4 		$395K Buy
+5,065
New +$407K 0.13% 272
2024
Q2 		– Sell
-3,835
Closed -$327K – 562
2024
Q1 		$327K Buy
+3,835
New +$301K 0.25% 158
2021
Q2 		– Sell
-3,574
Closed -$397K – 722
2021
Q1 		$397K Buy
+3,574
New +$442K 0.12% 330

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgefront Capital's HAE Position: Q2 2026 in Review

Bridgefront Capital sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 14,363 shares — an estimated $809K sold.

Bridgefront Capital first reported a position in HAE in Q1 2021 and held it in 7 quarters. The position peaked at $820K in Q4 2025. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Bridgefront Capital reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 14,363 Haemonetics shares in Q2 2026, an estimated $809K.
  • Bridgefront Capital first reported a position in Haemonetics in Q1 2021 and held it in 7 quarters.
  • Bridgefront Capital's Haemonetics position peaked at $820K in Q4 2025.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.